PMID- 32484365
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1744-8379 (Electronic)
IS  - 1473-7167 (Linking)
VI  - 21
IP  - 2
DP  - 2021 Apr
TI  - Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated 
      adverse events, for migraine prophylaxis in Spain.
PG  - 285-297
LID - 10.1080/14737167.2020.1768850 [doi]
AB  - Objective: To compare the cost of adverse events (AEs) associated with preventive 
      treatment of migraine with fremanezumab, versus erenumab, galcanezumab, and 
      onabotulinumtoxinA.Methods: A probabilistic modeling analysis was performed, 
      using second-order Monte Carlo simulations, with 1,000 simulations, in patients 
      with at least 4 days of migraine per month, from the perspective of the National 
      Health System and a time horizon of 12 weeks. The frequency of AEs described in 
      the clinical trials was analyzed with 12 weeks of treatment. Unit costs (euro) of 
      management of AEs were obtained from public health prices, expert panels, and 
      published Spanish studies.Results: Fremanezumab would generate average savings of 
      -euro469 (95% CI -euro303; -euro674) versus erenumab, -euro268 (95% CI -euro171; -euro391) versus 
      galcanezumab, -euro1,100 (95% CI -euro704; -euro1,608) or -euro1,295 (95% CI -euro835; -euro1,893) 
      versus onabotulinumtoxinA using real-life or clinical trial data, 
      respectively.Conclusions: The different safety profile of treatment with 
      fremanezumab, compared to erenumab, galcanezumab, and onabotulinumtoxinA, would 
      generate savings in health-care resources in all the scenarios considered.
FAU - Irimia, Pablo
AU  - Irimia P
AD  - Department of Neurology and Neurosurgery, Navarra University Clinic, Pamplona, 
      Spain.
FAU - Santos-Lasaosa, Sonia
AU  - Santos-Lasaosa S
AD  - Neurology Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain.
AD  - Instituto de Investigacion Sanitaria Aragon (IISA), Zaragoza, Spain.
FAU - Garcia Bujalance, Laura
AU  - Garcia Bujalance L
AD  - Teva Pharma Spain, Madrid, Spain.
FAU - Ramos Pinazo, Luis
AU  - Ramos Pinazo L
AD  - Teva Pharma Spain, Madrid, Spain.
FAU - Rubio-Rodriguez, Dario
AU  - Rubio-Rodriguez D
AD  - Health Value, Madrid, Spain.
FAU - Rubio-Terres, Carlos
AU  - Rubio-Terres C
AD  - Health Value, Madrid, Spain.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200602
PL  - England
TA  - Expert Rev Pharmacoecon Outcomes Res
JT  - Expert review of pharmacoeconomics & outcomes research
JID - 101132257
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (fremanezumab)
RN  - 55KHL3P693 (galcanezumab)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - EC 3.4.24.69 (onabotulinum toxin A)
RN  - I5I8VB78VT (erenumab)
SB  - IM
MH  - Antibodies, Monoclonal/administration & dosage/*adverse effects/economics
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse 
      effects/economics
MH  - Botulinum Toxins, Type A/administration & dosage/*adverse effects/economics
MH  - Cost Savings
MH  - Costs and Cost Analysis
MH  - Health Care Costs/*statistics & numerical data
MH  - Humans
MH  - Migraine Disorders/economics/*prevention & control
MH  - Monte Carlo Method
MH  - Probability
MH  - Spain
OTO - NOTNLM
OT  - Fremanezumab
OT  - adverse effects
OT  - cost
OT  - erenumab
OT  - galcanezumab
OT  - migraine disorders
OT  - onabotulinumtoxinA
EDAT- 2020/06/03 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1080/14737167.2020.1768850 [doi]
PST - ppublish
SO  - Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):285-297. doi: 
      10.1080/14737167.2020.1768850. Epub 2020 Jun 2.